

CMP: ₹ 1254

Target: ₹ 1190 (-5%)

Target Period: 12months

HOLD

June 28, 2020

Poultry stagnates; future hinges on animal healthcare

FY20 revenues grew a mere 2.9% mainly due to 4% decline in poultry segment (66% of revenues) amid lower vaccination drive due to sharp increase in maize prices and Covid-19 (C19). Animal healthcare segment grew 22% YoY to ₹ 139.6 crore (26% of revenues), driven by strong export growth and lower base. EBITDA margins contracted 798 bps YoY to 30.2% mainly due to increase in field force count (140-150 from 80) and negative operational leverage. EBITDA de-grew 18.6% YoY to ₹ 55.4 crore. PAT fell 29.8% to ₹ 29.2 crore due to a below expected operational performance.

Key conference call takeaways

- Exports grew 63% in FY20 despite delayed consignments in Q4 amid C-19. Hester has guided for 100% export growth in FY21
- Hester is one of the two suppliers for the National Animal Disease Control Programme of the Government of India for Brucella vaccine. However, this tender has been delayed due to C19, which it expects to start in couple of months
- It has 35% market share in Indian poultry vaccines. Growth in this division is expected to be in line with the market. Animal health segments is expected to remain strong given robust export growth, domestic tenders and lower base
- Hester initiated the development of a vaccine against C19 disease. The management expects to start animal trials by November 2021 and expects final vaccine in FY22. Hester is looking at C19 vaccine as platform to foray into human vaccine segment
- Tanzania projects commercial sales are expected to start from December 2020 and are expected to reach breakeven by CY22
- Hester has completed all major capex in near term. It is awaiting ₹ 20 crore grant for Tanzania project from Bill Gates Foundation
- It entered into a technical collaboration agreement with Nova Pharma in Egypt. Under this agreement, Hester would transfer technology to manufacture veterinary vaccines. Hester will get technology fees and marketing rights for the full range of vaccines manufactured at Nova Pharma


Valuation & Outlook

The poultry vaccine business faced significant headwinds in FY20 as a sharp spike in maize prices (accounting for ~50% of feed cost) hampered the vaccination drive among poultry farmers. Just when things were returning to normalcy, came the Covid disturbance. Uncertainty remains upon normalisation of chicken, egg consumption pattern to pre-Covid level. The animal health segment, on the other hand, is expected to remain strong due to tenders and strong export potential. However, fortunes in the poultry segment would continue to weigh on sentiments. We arrive at a target price of ₹ 1190 based on 22x FY22 EPS of ₹ 54.

HESTER

Particulars				
Particular	Amount			
Market Capitalisation	₹1067 crore			
Debt (FY20)	₹115 crore			
Cash (FY20)	₹24 crore			
EV	₹1158 crore			
52 week H/L (₹)	2048/864			
Equity capital	₹8.5 crore			
Face value (₹)	₹10			





Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Mitesh Shah, CFA mitesh.sha@icicisecurities.com

Sudarshan Agarwal sudarshan.agarwal@icicisecurities.com

Key Financial Summary					
(₹Crore)	FY19	FY20	FY21E	FY22E	CAGR (FY20-22E) %
Revenues	178.1	183.3	199.6	252.1	17.3
EBITDA	68.1	55.4	53.9	80.0	20.2
EBITDA margins(%)	38.2	30.2	27.0	31.7	
Net Profit	41.6	29.2	23.1	45.9	25.5
EPS (3)	48.9	34.3	27.1	54.0	
PE (x)	25.7	36.6	46.3	23.2	
EV to EBITDA (x)	9.9	13.1	12.8	8.1	
Price to book (x)	6.0	5.3	4.9	4.2	
RoNW (%)	23.4	14.5	10.5	18.0	
RoCE (%)	23.3	14.5	11.3	19.1	

Company Update

Source: ICICI Direct Research; Company

Exhibit 1: Variance Analysis

a

	FY20	FY19	YoY (%)	Comments
Revenue	183.3	178.1	2.9	Strong growth in Animal health segment was largely offset by impact of recessionary condition in Poultry vaccine segment and C19
Raw Material Expenses	19.7	28.9	-31.8	Improvement in gross margin on account of change in product mix.
Employee Expenses	40.7	28.9	40.6	Increased mainly due to addition of field force
D ther E xpenditure	67.5	52.2	29.3	Increased mainly due to higher marketing and promotional expenses
EBITDA	55.4	68.1	-18.6	
EBITDA (%)	30.2	38.2	-798.1	Decline mainly due to field force addition and negative operational leverage
nterest	7.4	6.6	11.2	
Depreciation	13.1	11.8	11.1	
O ther Income	6.4	7.2	-11.7	
PBT before EO & Forex	41.3	56.9	-27.3	
Forex & EO	0.0	0.0	NA	
PBT	41.3	56.9	-27.3	
Tax	10.3	16.2	-36.1	
PAT before MI	31.0	40.7	-23.8	
MI	1.8	-0.9	-309.6	
Net Profit	29.2	41.6	-29.8	YoY decline mainly due to lower operational performance
Key Metrics				
Poultry Healthcare	120.3	125.8	-4.3	Decline mainly due to recessionary condition throughout the year and C19 impact
Animal Healthcare	47.3	38.8	22.0	YoY increase mainly due to lower base and strong export growth

Source: ICICI Direct Research

Financial Summary

(Year-end March)	FY19	FY20	FY21E	FY22E
Revenues	178.1	183.3	199.6	252.1
Growth (%)	173.5	2.9	8.9	26.3
Raw Material Expenses	28.9	19.7	21.5	27.1
Employee Expenses	28.9	40.7	50.7	59.3
O ther E xpenditure	52.2	67.5	73.5	85.7
Total Operating Expenditure	110.0	127.9	145.6	172.1
EBITDA	68.1	55.4	53.9	80.0
Growth (%)	209.3	-18.6	-2.7	48.4
Interest	6.6	7.4	9.2	5.2
Depreciation	11.8	13.1	18.4	19.5
O ther Income	7.2	6.4	7.0	8.8
PBT before Exceptional Item	56.9	41.3	33.4	64.2
Less: Forex & Exceptional It	0.0	0.0	0.0	0.0
PBT	56.9	41.3	33.4	64.2
Total Tax	16.2	10.3	8.3	16.0
РАТ	41.6	29.2	23.1	45.9
Adjusted PAT	41.6	29.2	23.1	45.9
Growth (%)	342.8	-29.8	-21.0	99.3
EPS	48.9	34.3	27.1	54.0
EPS (Adjusted)	48.9	34.3	27.1	54.0

Exhibit 3: Cash Flow Statem	•			
(Year-end March)	FY19	FY20	FY21E	FY22E
Profit/(Loss) after taxation	41.0	30.4	23.1	45.9
Add: Depreciation & Amortiz	11.8	13.2	18.4	19.5
Add: Interest	6.6	7.7	9.2	5.2
Net Increase in Current Asse	-9.1	-36.1	1.5	2.9
Net Increase in Current Liabil	-3.2	22.5	-6.2	3.0
CF from operating activitie	47.2	37.6	45.9	76.5
(Inc)/dec in Fixed Assets	-22.5	-72.5	-20.0	-20.0
(Inc)/dec in Investments	0.0	0.0	0.0	0.0
Other Investing Activities	1.9	-2.9	20.6	1.6
CF from investing activitie:	-20.7	-75.5	0.6	-18.4
Proceeds from issues of Equ	0.0	0.0	0.0	0.0
Proceeds/(Repayment) Loan	19.0	28.2	0.0	-50.0
(Payment) of Dividend and Di	-10.3	-7.2	-5.2	-10.3
Other Financing Activities	-6.1	-2.4	-9.2	-5.2
CF from financing activitie	2.7	18.6	-14.3	-65.4
Net Cash flow	29.2	-19.2	32.1	-7.3
Opening Cash	13.4	42.1	23.5	55.7
Closing Cash	42.5	22.9	55.7	48.3
FCF	24.6	-34.9	25.9	56.5

Source: ICICI Direct Research

Exhibit 4: Balance Sheet (₹ crore)						
(Year-end March)	FY19	FY20	FY21E	FY22E		
Equity Capital	8.5	8.5	8.5	8.5		
Reserve and Surplus	169.0	192.6	210.5	246.1		
Total Shareholders funds	177.5	201.1	219.0	254.6		
Total Debt	80.9	114.5	114.5	64.5		
Deferred Tax Liability	10.7	8.8	9.3	9.7		
Minority Interest	3.7	5.4	5.7	6.0		
O ther Non Current Liabilities	0.4	7.0	27.4	28.8		
Source of Funds	273.1	336.9	375.8	363.6		
Gross Block - Fixed Assets	215.7	226.7	316.7	336.7		
Accumulated Depreciation	71.1	84.2	102.6	122.1		
Net Block	144.6	142.5	214.2	214.6		
Capital WIP	7.1	74.2	4.2	4.2		
Net Fixed Assets	151.7	216.7	218.3	218.8		
Total Intangible Assets	0.0	0.0	0.0	0.0		
Investments	0.0	0.0	0.0	0.0		
Inventory	50.8	64.0	65.6	71.9		
Cash	42.1	23.5	55.7	48.3		
Debtors	31.7	58.4	54.7	44.9		
Loans & Advances & Other (18.1	12.6	13.2	13.8		
Total Current Assets	142.7	158.5	189.1	178.9		
Creditors	8.8	18.6	10.9	12.4		
Provisions & Other CL	17.4	29.9	31.4	32.9		
Total Current Liabilities	26.2	48.5	42.3	45.3		
Net Current Assets	116.5	110.0	146.8	133.6		
LT L& A, O ther Assets	4.9	10.2	10.7	11.2		
Deferred Tax Assets	0.0	0.0	0.0	0.0		
Application of Funds	273.1	336.9	375.8	363.6		

Source: ICICI Direct Research

(Year-end March)	FY19	FY20	FY21E	FY22E
Per share data (₹)				
EPS	48.9	34.3	27.1	54.0
Cash EPS	36.1	26.6	21.0	41.9
BV	208.6	236.4	257.4	299.3
DPS	12.8	7.7	6.1	12.1
Cash Per Share	83.6	99.0	120.6	143.5
Operating Ratios (%)				
Gross Profit Margins	83.8	89.2	89.2	89.2
EBITDA margins	38.2	30.2	27.0	31.7
Net Profit margins	23.3	15.9	11.6	18.2
Inventory days	104.1	127.4	120.0	104.1
Debtor days	65.0	116.4	100.0	65.0
Creditor days	17.9	37.1	20.0	17.9
Asset Turnover	0.7	0.5	0.5	0.7
EBITDA conversion rate	69.3	67.9	85.1	95.6
Return Ratios (%)				
RoE	23.4	14.5	10.5	18.0
RoCE	23.3	14.5	11.3	19.1
RoIC	80.2	75.5	28.9	46.8
Valuation Ratios (x)				
P/E	25.7	36.6	46.3	23.2
EV / EBITDA	9.9	13.1	12.8	8.1
EV / Revenues	3.8	4.0	3.5	2.6
Market Cap / Revenues	3.6	3.5	3.2	2.5
Price to Book Value	6.0	5.3	4.9	4.2
Solvency Ratios				
Debt / Equity	0.5	0.6	0.5	0.3
Debt/EBITDA	1.2	2.1	2.1	0.8
Current Ratio	3.8	2.8	3.2	2.9

Source: ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%; Hold: -5% to 15%; Reduce: -5% to -15%; Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

We /l, Siddhant Khandekar, Inter CA, Mitesh Shah, CFA, Sudarshan Agarwal, PGDM(Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment must be taken in substitution for the exercise of independent yealuate the investment risks. The value and return on investment may ease of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risk associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.